Related Experiment Videos
The interaction between herpes simplex virus and human immunodeficiency virus
1University of Washington, Seattle, WA 98104, USA. ccelum@u.washington.edu
Herpes : the Journal of the IHMF
|April 30, 2004
Summary
Herpes simplex virus type 2 (HSV-2) infection significantly increases HIV acquisition risk. Treating HSV-2 may reduce HIV transmission by lowering viral shedding, highlighting its role as a modifiable risk factor.
Area of Science:
- Virology
- Immunology
- Epidemiology
Background:
- Herpes simplex virus (HSV) seropositivity is linked to increased HIV acquisition risk.
- HSV-2 infection specifically doubles the risk of acquiring HIV.
Purpose of the Study:
- To explore the mechanisms by which HSV-2 increases HIV acquisition and transmission.
- To evaluate the potential of antiherpetic therapy in reducing HIV transmission.
Main Methods:
- Review of meta-analyses and in vivo/in vitro studies on HSV-2 and HIV interactions.
- Analysis of the impact of HSV-2 reactivation on epithelial barriers and CD4 cell recruitment.
- Assessment of HSV regulatory proteins' role in HIV replication and shedding.
Main Results:
- HSV-2 reactivation disrupts epithelial barriers, recruiting HIV target cells (CD4 cells) to lesions.
- HSV proteins (ICP0, ICP4, VP16) may enhance HIV replication and mucosal shedding.
- Co-infection with HIV and HSV-2 leads to more frequent HSV recurrences, linked to immunosuppression.
Conclusions:
- HSV-2 is a significant, modifiable risk factor for HIV acquisition and transmission.
- Targeted testing, counseling, and antiviral suppression for HSV-2 in HIV-positive individuals are recommended.
- Further trials are needed to confirm the efficacy of antiherpetic therapy in reducing HIV transmission.